Pfizer's stock (NYSE:PFE) has been fluctuating with lows reported at $28 and at times falling to 10-year lows. Despite these lows, the stock maintains a 6% yield and a secure dividend, piquing the interest of investors. Predictably, there have been downturns, with shares falling 0.6% and a noticeable dip after Pfizer reset 2024 COVID expectations. On the flip side, the company's shares also surged, particularly after beating earnings estimates and revealing a positive outlook fueled by cost cuts and smaller-than-feared drop in Covid drug sales. The Paxlovid surprise contributed to the stock's sizeable gains and sustained investor interest. Notably, Pfizer managed to beat estimates on several occasions and subesquently revised its full-year outlook upwards. That said, concerns persist due to weaker COVID demand leading to a cut in their earnings outlook. Even with the lows, some analysts predict stock upturn for Pfizer, arguing it is undervalued. Investors are also advised to take note of Pfizer's strategy of focusing on cancer drugs as a business pivot after the decline in Covid demand.
Pfizer Stocks News Analytics from Fri, 13 Oct 2023 07:00:00 GMT to Thu, 09 May 2024 23:20:35 GMT -
Rating 5
- Innovation -2
- Information 7
- Rumor -4
